Australia; VIC; QLD
CSL will begin immediate development of an anti-SARS-CoV-2 plasma product with the potential to treat people with serious complications of COVID-19, particularly those whose illness is progressing towards the need for ventilation. The investigational product, COVID-19 Immunoglobulin, will be developed using donations of plasma collected by Australian Red Cross Lifeblood from people who have recovered from COVID-19. This briefing will provide journalists with the opportunity to ask health experts about the treatment ahead of a media conference with The Hon. Greg Hunt at 11.00am (AEST).
From:
Speakers:
Date: Wed 6 May 2020
Start Time: 09:30am AEST
Duration: Approx 45 min
Venue: Online
A full recording of the briefing is available via the link below
Note: Not all attachments are visible to the general public. Research URLs will go live after the embargo ends.
Sign In
